Agios Pharm Total Stockholder Equity Over Time
| AGIO Stock | USD 55.68 0.14 0.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Agios Pharm Performance and Agios Pharm Correlation. Agios |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare Agios Pharm and related stocks such as Mereo BioPharma Group, Blueprint Medicines Corp, and Day One Biopharmaceu Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MREO | 101.5 M | 101.5 M | 101.5 M | 101.5 M | 101.5 M | 101.5 M | 79.3 M | 62.5 M | 32.8 M | 40.3 M | (15 M) | 88 M | 61.9 M | 50.5 M | 44.6 M |
| BPMC | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | 35.4 M | 144 M | 213.1 M | 624 M | 419 M | 464.4 M | 1.5 B | 970.7 M | 514.7 M | 130.6 M | 124.1 M |
| DAWN | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (54.2 M) | (127.5 M) | (269.7 M) | 346.5 M | 363.9 M |
| BMRN | 29.4 M | 773 M | 1 B | 1.3 B | 1.5 B | 2.4 B | 2.8 B | 2.8 B | 3 B | 3.1 B | 4.1 B | 4.3 B | 4.6 B | 5 B | 5.2 B |
| IDYA | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (15.7 M) | (48.9 M) | 100.4 M | 198.3 M | 301.5 M | 349.5 M | 621.1 M | 652.1 M |
| ANAB | 145 K | 145 K | 145 K | 145 K | 6 M | 42.3 M | 39.3 M | 307.6 M | 486.4 M | 405 M | 396.7 M | 356.4 M | 262.1 M | 88.1 M | 83.7 M |
| MGTX | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (47.4 M) | 81.1 M | 190.8 M | 238.6 M | 185.4 M | 117.7 M | 138.2 M | 122 M |
| KROS | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 5.5 M | 261.7 M | 243.2 M | 277.4 M | 332.2 M | 207.7 M |
| KYMR | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (74.4 M) | 283.9 M | 459.6 M | 490.2 M | 395 M | 278.6 M |
| RVMD | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 96.7 M | 152.5 M | 474.7 M | 602.6 M | 685.2 M | 1.8 B | 1.9 B |
| CCCC | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (79.8 M) | (112 M) | 280.8 M | 389.6 M | 289.2 M | 246.1 M | 185.9 M |
| NRIX | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (36.8 M) | (57.7 M) | 290.3 M | 342.3 M | 303.7 M | 200.5 M | 230.6 M | 191.1 M |
| RLAY | (110.9 M) | (110.9 M) | (110.9 M) | (110.9 M) | (110.9 M) | (110.9 M) | (110.9 M) | (110.9 M) | (110.9 M) | (180.4 M) | 763.3 M | 897.8 M | 950.2 M | 752 M | 563.2 M |
| STOK | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | 105.1 M | 224.4 M | 286.1 M | 217.8 M | 184.8 M | 159.6 M | 184.9 M |
| PLRX | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | (882 K) | (435 K) | 283.1 M | 199.1 M | 313.3 M | 473.6 M | 497.3 M |
| BDTX | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (15.5 M) | (51 M) | (118.2 M) | (243.8 M) | (335 M) | 116.7 M | 122.6 M |
| ARVN | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 24 M | 245.9 K | 136.7 M | 226.7 M | 642.3 M | 781.7 M | 564.9 M | 660 M | 417.5 M |
| SNDX | (29.3 M) | (29.3 M) | (29.3 M) | 11.8 M | (5.7 M) | 66.7 M | 84.1 M | 104.3 M | 53 M | 31.6 M | 252.2 M | 408.4 M | 467.4 M | 554.2 M | 581.9 M |
| COGT | 52.4 M | 52.4 M | 52.4 M | 52.4 M | 52.4 M | 52.4 M | 52.4 M | 28.3 M | 60.2 M | 31.8 M | 234.7 M | 214.2 M | 255.7 M | 257.8 M | 156.1 M |
| CGEM | (1 M) | (1 M) | (1 M) | (1 M) | (1.1 M) | (1.2 M) | (574.9 K) | (20.7 M) | (20.7 M) | (40.8 M) | (77.6 M) | 422.6 M | 535 M | 453.7 M | 476.4 M |
| KALV | (28.3 M) | (28.3 M) | (28.3 M) | (33.7 M) | (4.6 M) | 49.3 M | 31.3 M | 27.3 M | 96.7 M | 83.8 M | 257.2 M | 185.1 M | 161 M | 206.6 M | 49.3 M |
| MRSN | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (42.7 M) | (55.6 M) | 70 M | 8.8 M | 78.3 M | 228.1 M | 121.7 M | 92.1 M | 36.9 M | 65.7 M |
Agios Pharm and related stocks such as Mereo BioPharma Group, Blueprint Medicines Corp, and Day One Biopharmaceu Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| Agios Pharm | AGIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 55.68
Check out Agios Pharm Performance and Agios Pharm Correlation. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Agios Pharm technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.